Peregrine Pharma (PPHM) Presents Strong Data from PS-Targeting Tumor Studies

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), reports new data from its phosphatidylserine (PS)-targeting tumor imaging studies were presented at the 2011 World Molecular Imaging Congress (WMIC) held September 7-10, 2011.

Key Highlights:

• A fragment of the fully human PS-targeting antibody PGN635 targets externalized PS on the blood vessels of prostate and breast tumors.
  
  
• Docetaxel increased the localization of the antibody to the tumors.
  
  
• These data provide a rationale to image PS expression for tumors and to monitor responses to chemotherapy.

"These preclinical data further validate the ability of our PS-targeting antibodies to image tumors and their potential in assessing the effectiveness of standard cancer therapies. These are two important applications that could help clinicians and researchers evaluate therapeutic responses early on in therapy. While keeping our main focus on advancing our Phase II clinical programs for our lead PS-targeting antibody bavituximab, we believe our imaging platform has broad potential in providing a visual assessment of a patient's response to therapy. This technology is nearing readiness for the clinic, either as an internal effort or in conjunction with a potential partner, and we look forward to advancing the program," said Steven W. King, president and chief executive officer of Peregrine.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
• Catalyst Pharmaceutical (CPRX) Reports Encouraging Data from CPP-115 Phase Ia
• Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter